Har­ris Poll notes in­crease in phar­ma rep­u­ta­tion among Amer­i­cans who know about GLP-1 drugs

GLP-1 med­ica­tions are help­ing to boost the phar­ma in­dus­try’s rep­u­ta­tion in the US. That’s ac­cord­ing to a Har­ris Poll run re­cent­ly to gauge gen­er­al pub­lic sen­ti­ment about the in­dus­try, and it in­clud­ed spe­cif­ic ques­tions about the GLP-1 drug cat­e­go­ry on be­half of End­points News.

55% of peo­ple who are tak­ing a GLP-1 or know some­one who is say they have a pos­i­tive per­cep­tion of the phar­ma in­dus­try. The num­ber drops to 50% among peo­ple who were fa­mil­iar with GLP-1s (but not tak­ing them or know any­one who is) and dips even fur­ther to 40% among those who are un­fa­mil­iar with the glucagon-like pep­tides class. The sam­ple size was 2,016 adults in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER